Galectin Therapeutics Inc (GALT) company profile
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
About Galectin Therapeutics
Pharmaceutical Preparations, SIC 2834
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies for fibrotic conditions and cancers. The company utilizes plant-derived complex carbohydrates to create compounds that inhibit galectin proteins, particularly galectin-3. Its lead drug candidate is belapectin, which is evaluated for treating metabolic dysfunction-associated steatohepatitis with cirrhosis and portal hypertension, as well as head and neck cancers. Additionally, the company develops orally administered small-molecule inhibitors through a joint venture subsidiary. Because all drug candidates remain in clinical or preclinical development, the firm has no commercial customers and directs its therapies toward patients suffering from chronic liver disease and life-threatening malignancies.
The company is headquartered in Norcross, Georgia, near Atlanta, and maintains a laboratory facility in the Boston, Massachusetts area. Its clinical trial footprint includes more than 150 study sites established across 14 countries, with operations and patient enrollment spanning the United States, Europe, and Latin America.
Summary of the business section of Galectin Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Galectin Therapeutics Inc
- Founded
- 2000
- Headquarters
- Norcross, GA
- Address
- 4960 Peachtree Industrial Boulevard, Suite 240 30071
- Phone
- (678) 620-3186
- Website
- galectintherapeutics.com
- Employees
- 9, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- GALT
- Exchange
- Nasdaq
- IPO date
- Sep 4, 2002
- Shares outstanding
- 101M, Aug 6, 2026
- Public float
- $109.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Mar 23, 2012
- SEC CIK
- 1133416
- CUSIP
- 363225202
- ISIN
- US3632252025
- FIGI
- BBG000BK6FP5
- Share class FIGI
- BBG001S9NYW2
- LEI
- 5299004HFYSAZM2ALW85
- EIN
- 04-3562325
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joel Lewis | President and CEO, Director | 778,260 |
| Khurram Jamil | Chief Medical Officer | 16,250 |
| Jack W. Callicutt | Chief Financial Officer | 7,614 |
| Richard E. Uihlein | Director | 52,523,297 |
| Harold H. Shlevin | Director | 28,768 |
| Henry Brem | Director | 0 |
| Kary Eldred | Director | 70,107 |
| Benjamin Carson Sr | Director | – |
| Gilbert F. Amelio | Director | 60,614 |
| Gilbert S. Omenn | Director | 66,769 |
| Elissa J. Schwartz | Director | 1,000 |
| Richard A. Zordani Jr. | Director | 44,083 |
| Kevin D. Freeman | Director | 137,269 |
| Marc Rubin | Director | 13,581 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.17M | $1.69M | $929.35K | $322 | – |
| FY2024 | $1.19M | $1.05M | $831.40K | $78 | – |
| FY2023 | $963.65K | $1.06M | $665.85K | $147 | – |
| FY2022 | $974.18K | $665.81K | $680.57K | $55 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Joel Lewis Chief Executive Officer & President | $624.00K | $312.00K | $182.76K | $56.02K | $1.17M | -1% |
| Khurram Jamil, M.D. Chief Medical Officer | $500.00K | $350.00K | $130.55K | $71.58K | $1.05M | +11% |
| Jack W. Callicutt Chief Financial Officer | $400.00K | $220.00K | $130.55K | $56.02K | $806.56K | +13% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had nine full-time employees, six of whom are involved primarily in management of our research and development and clinical trials and three who were involved primarily in management and administration of our Company.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?